





UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE		FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/827,133	04/19/2004		Michael S. Allen	6704-29	2875	
43463	7590	04/24/2006		EXAMINER		
•		CY, SMITH, SCH	DUNSTON, JENNIFER ANN			
222 LAKEV SUITE 800	IEW AVE		ART UNIT	PAPER NUMBER		
WEST PALM BEACH, FL 33401-6112				1636		
				DATE MAILED: 04/24/2006	6	

Please find below and/or attached an Office communication concerning this application or proceeding.

Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)		
10/827,133	ALLEN ET AL.		
Examiner	Art Unit		
Jennifer Dunston	1636		

	Jennier Duriston	1000						
The MAILING DATE of this communication appear	ars on the cover sheet with the c	orrespondence add	ress					
THE REPLY FILED 10 April 2006 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE.								
1. The reply was filed after a final rejection, but prior to or on this application, applicant must timely file one of the follow places the application in condition for allowance; (2) a Not a Request for Continued Examination (RCE) in compliance time periods:	ving replies: (1) an amendment, aff tice of Appeal (with appeal fee) in o se with 37 CFR 1.114. The reply mu	idavit, or other evider compliance with 37 C	nce, which FR 41.31; or (3)					
a) The period for reply expiresmonths from the mailing		to the foretaction wh	introducto Internation					
b) The period for reply expires on: (1) the mailing date of this A no event, however, will the statutory period for reply expire a Examiner Note: If box 1 is checked, check either box (a) or (ater than SIX MONTHS from the mailing	g date of the final rejecti	on.					
TWO MONTHS OF THE FINAL REJECTION. See MPEP 70	06.07(f).							
Extensions of time may be obtained under 37 CFR 1.136(a). The date have been filed is the date for purposes of determining the period of ext under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the set forth in (b) above, if checked. Any reply received by the Office later may reduce any earned patent term adjustment. See 37 CFR 1.704(b) NOTICE OF APPEAL	ension and the corresponding amount shortened statutory period for reply orig than three months after the mailing da	of the fee. The appropr inally set in the final Offi	iate extension fee ce action; or (2) as					
2. The Notice of Appeal was filed on A brief in comp filing the Notice of Appeal (37 CFR 41.37(a)), or any external notice of Appeal has been filed, any reply must be filed AMENDMENTS	nsion thereof (37 CFR 41.37(e)), to	avoid dismissal of th	ns of the date of e appeal. Since					
3. The proposed amendment(s) filed after a final rejection,			ecause					
(a) They raise new issues that would require further co		TE below);						
(b) They raise the issue of new matter (see NOTE belo		duaina or simplifuina	the iccurs for					
(c) They are not deemed to place the application in bet appeal; and/or			the issues for					
(d) They present additional claims without canceling a		ected claims.						
NOTE: <u>See continuation sheet</u> . (See 37 CFR 1.11			(DTOL 204)					
4. The amendments are not in compliance with 37 CFR 1.13		mpliant Amendment	(PTOL-324).					
5. Applicant's reply has overcome the following rejection(s)		timely filed emendme	ent concoling the					
6. Newly proposed or amended claim(s) would be al non-allowable claim(s).								
7. To purposes of appeal, the proposed amendment(s): a) how the new or amended claims would be rejected is provided the status of the claim(s) is (or will be) as follows:	☑ will not be entered, or b) ☐ wi vided below or appended.	II be entered and an e	explanation of					
Claim(s) allowed:								
Claim(s) objected to:								
Claim(s) rejected: <u>1-4, 6-11, 15-23, 25 and 26</u> . Claim(s) withdrawn from consideration:								
AFFIDAVIT OR OTHER EVIDENCE								
8. The affidavit or other evidence filed after a final action, but because applicant failed to provide a showing of good answas not earlier presented. See 37 CFR 1.116(e).	t before or on the date of filing a N d sufficient reasons why the affidat	otice of Appeal will <u>no</u> vit or other evidence i	ot be entered s necessary and					
9. The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to a showing a good and sufficient reasons why it is necessary	vercome all rejections under appe	al and/or appellant fa	ils to provide a					
10. The affidavit or other evidence is entered. An explanatio	n of the status of the claims after e	ntry is below or attac	hed.					
REQUEST FOR RECONSIDERATION/OTHER	. done NOT place the combination :	a condition for alleurs	nco hocauco:					
11. The request for reconsideration has been considered by See continuation sheet.			nce because.					
12. ☐ Note the attached Information Disclosure Statement(s).13. ☐ Other:	(PTO/SB/08 or PTO-1449) Paper N	No(s)						

Application/Control Number: 10/827,133

Art Unit: 1636

CONTINUATION SHEET

The amendment filed 4/10/2006 under 37 CFR 1.116 in reply to the final rejection has NOT been entered. The final Office action, mailed 2/10/2006, is maintained.

The proposed amendment to claim 1 requires further search and/or consideration. The scope of the proposed claim, filed 4/10/2006, is broader than the enabled subject matter indicated on pages 4-9 of the final Office action. The difference in scope between the newly amended claims and the Examiner's suggestion, which was presented in the scope of enablement rejection in the previous Office action, will require further search and/or consideration. Thus, claim 1 and claims that depend therefrom would require further search and/or consideration.

The proposed amendment to claim 2 requires further search and/or consideration and raises the issue of new matter. The claim is drawn to a nucleic acid construct comprising a nucleic acid encoding LuxA modified with a sequence that specifically binds a tail-specific protease and a nucleic acid encoding LuxB modified with a sequence at its carboxy terminus that specifically binds to a protein associated with a ubiquitin-proteasome pathway. This combination of elements was not previously presented, and thus requires further search and/or consideration. Further, this claim raises issues of new matter in that the specification does not disclose a nucleic acid encoding both LuxA and LuxB where LuxA is modified by a tail-specific protease sequence and LuxB is modified with a protein associated with a ubiquitin-proteasome pathway. The specification discloses modified LuxA and LuxB, wherein both proteins are modified by a SEQ ID NO: 8 for use in bacteria, and wherein both proteins are modified by the 178 amino acid C-terminus of the G1 cyclin Cln2 for use in yeast. The response does not point to portions of the specification, claims or drawings, as originally filed, for support for the

Application/Control Number: 10/827,133

Art Unit: 1636

amendment of claim 2. Therefore, proposed claim 2 represents a departure from the specification, claims and drawings as originally filed.

The proposed amendment to claim 4 requires further search and/or consideration in that the dependency of the claim has been changed. Thus, the scope of claim 4 has been altered by the proposed amendment. This change in scope requires further search and/or consideration.

With regard to the rejection of claim 4 under 35 U.S.C. 112, 1st paragraph, all remarks are directed to the newly amended claims. As discussed above, the amendments have not been entered and therefore the arguments are moot and will not be addressed.

With regard to the rejection of claims 1-4, 6-11, 15-23 and 25-26 under 35 U.S.C., 1st paragraph, all remarks are directed to the newly amended claims. As discussed above, the amendments have not been entered, and therefore the arguments are moot and will not be addressed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jennifer Dunston whose telephone number is 571-272-2916. The examiner can normally be reached on M-F, 9 am to 5 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Remy Yucel can be reached at 571-272-0781. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR, http://pair-direct.uspto.gov) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your

Application/Control Number: 10/827,133

Art Unit: 1636

application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public.

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.

Jennifer Dunston, Ph.D. Examiner
Art Unit 1636

jad

CELINE QIAN, PH.D. PRIMARY EXAMINER

72